Myfortic (Mycophenolic Acid)

Mycophenolic acid inhibits the enzyme inosine monophosphate dehydrogenase, which is essential for the synthesis of guanosine nucleotides. By limiting guanosine availability, the drug suppresses the proliferation of activated T and B lymphocytes, reducing the immune response that can damage a transplanted organ.

The dose of Myfortic is individualized by the prescribing clinician based on factors such as the type of organ transplanted, the patient’s renal function, concomitant immunosuppressants, and therapeutic drug monitoring results. No fixed dosing regimen is provided here.

Myfortic is classified as a prescription‑only immunosuppressant, and its safety in pregnancy or lactation has not been fully established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under specialist guidance.

To order Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Myfortic and azathioprine are antimetabolite immunosuppressants, but Myfortic selectively inhibits inosine monophosphate dehydrogenase, leading to a more targeted suppression of lymphocyte proliferation. Azathioprine interferes with purine synthesis more broadly, which can result in a different side‑effect profile and dosing considerations.

Myfortic should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use to maintain stability.

Myfortic is taken orally, usually as whole tablets or capsules, with or without food as directed by the prescriber. The exact administration schedule, including timing relative to other immunosuppressants, is determined by the treating physician.

Serious risks include severe leukopenia or neutropenia, opportunistic infections such as Pneumocystis jirovecii pneumonia, and rare gastrointestinal perforation. Patients should be monitored regularly for blood count changes and signs of infection, and any severe symptoms should prompt immediate medical evaluation.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any of the tablet components. It should also be avoided in individuals with active, uncontrolled infections, severe bone‑marrow suppression, or those who are pregnant without a clear benefit outweighing the risk.